Anti-Mouse/Human CD45R (B220) (Clone RA3-6B2) – Purified

Pricing & Details

Product No.C259
Clone
RA3-6B2
Protein
CD45R
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
B220
Isotype
Rat
IgG2a κ
Applications
Act
,
FA
,
FC
,
IHC FF
Prod No.
Size
Price
Avail.
Qty
Add to cart
C259-50 µg
50 µg
$20.00
In stock
Max:
Min: 1
Step: 1
C259-500 µg
500 µg
$70.00
In stock
Max:
Min: 1
Step: 1

Data

Antibody Details

Product Details

Reactivity Species
Mouse/Human
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Product Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this RA3-6B2 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
Act
FA
IHC (Frozen)
Additional Reported Applications For Relevant Conjugates ?
IP
For specific conjugates of this clone, review literature for suggested application details.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rat Anti-Mouse/Human CD45R (Clone RA3-6B2) recognizes the B-cell determinant (Mr 220 kD) of the CD45 molecule.
Antigen Distribution
The CD45R antigen is present on mouse B-cells, B-cell precursors and lytically active subsets of lymphokine-activated killer cells (NK cells and non-MHC restricted CTL).
Background
CD45 is a 180-240kD glycoprotein member of the protein tyrosine phosphatase (PTP) family known for its involvement in regulating a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. CD45 and its isoforms are vital regulators of T- and B-cell antigen receptor signaling. CD45 functions through its extracellular domain or through its cytoplasmic domain, and serves as a negative regulator of cytokine receptor signaling via JAK kinase suppression. The large extracellular domain is highly glycosylated, and its multiple isoforms allow extensive variation in the structure of its side chains. CD45 isoforms show cell-type and differentiation-stage specific expression that can be used as markers that identify and distinguish between different types of immune cells. CD45R is an isoform of CD45 with a molecular weight of 220 kD. CD45R contains all three possible exons (A, B, and C); making it the longest protein generated from alternative splicing with a migration at 200 kD when isolated from T cells. Furthermore, B cells express CD45R with heavier glycosylation, bringing the molecular weight to 220 kD, hence the name B220. Notably, B220 expression is not only restricted to B cells and may also be expressed on activated T cells, on a subset of dendritic cells, and on other antigen-presenting cells. Additionally, activated and memory T lymphocytes express CD45RO which facilitates T cell activation. CD45RO lacks all three possible exons (A, B, and C), making it the shortest CD45 isoform.

Antigen Details

Protein
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
PubMed
NCBI Gene Bank ID
Research Area
Cell Biology
.
Immunology
.
Inhibitory Molecules
.
Neuroscience
.
Neuroscience Cell Markers

References & Citations

1. Coffman, B. et al. (1982) Immunological Rev. 69:5
2. Zuhair, K. et al. (1993) J. Immunol. 150:17
3. Asensi, V. et al. (1989) Immunology 68:204
Flow Cytometry
IHC

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.